Endocrine Abstracts

The analogues of GLP-1(aGLP1) are a new class of anti-diabetic agents, administered subcutaneously for the treatment of Diabetes Mellitus type 2 (DM2). In the Portuguese market, there are two aGLP1 currently available: Liraglutide (once-daily administration) and Exenatide (once-weekly administration). They mimic the GLP-1, produced in the small intestine, stimulated by foods at this region, increasing the production of insulin, decreasing the satiety and slowing gastric emptying.

Objectives: Impact assessment of aGLP1 in patients with DM2 followed in the consultation of Diabetes.

Methods: Retrospective study of patients with DM2 followed in consultation, using aGLP1, since January 2014 to December 2015. Were evaluated: demographic data, the anti-diabetic medication used before the introduction of the drug, metabolic control and the weight on the 0, 3 and 6 months(M). Data were analysed according to descriptive statistical methods.

Results: Were observed 80 patients, 65% male, with average of 58.4±9.4 years. The initial mean HbA1c was 8.0% (5.1–11.6) and the average initial weight was 109.9 Kg (between 72 and 132). 76.9% of patients were under non-insulin anti-diabetics (NIA), 12.8% under NIA+long-acting insulin, 10.3% under NIA+long-acting insulin+rapid-acting insulin. In 13.3% it was the first therapeutic choice. In 31.4% was done an exchange of pharmacological class and the remaining therapeutic add-on. 12.8% abandoned therapy by gastro-intestinal side effects. The HbA1c to 3 M reduced on average −0.84% (−3.0 and +1.7), however in 15% there was an increase and 6 M a mean variation of −1.3% (−3.8 to +2.5). The weight reduced on average −2.98 kg (−15 to 0) to 3 M, no increased weight and 10% remained weight, and reduced −5.1 kg (−16 to +2) at 6 M.

Conclusions: Patients with DM2 medicated with aGLP1 presented benefits at the level of HbA1c and the weight up to 6 months. The extension of this analysis will assess the long-term results.